II. Indications
- Severe, refractory COPD with Chronic Bronchitis and frequent exacerbations
III. Mechanism
- Combined PDE3 and PDE4 Inhibitor
- Increases lung intracellular cAMP
- Bronchodilates and reduces airway inflammation
IV. Medications
- Ensifentrine Inhalation aqueous suspension: 3 mg/2.5 mL (unit-dose ampules)
V. Dosing
- Shake Ensifentrine ampule before nebulizing (solution may appear cloudy and yellow)
- Nebulize 3 mg (one ampule) twice daily
VI. Adverse Effects
- Uncommon adverse effects
- Paradoxical bronchospasm
- Suicidality
- Hypertension
- Diarrhea
- Urinary Tract Infections
- Back Pain
VII. Safety
- Unknown safety in pregnancy
- Unknown safety in Lactation
VIII. Efficacy
- Efficacy data is limited as of 2024
- Very expensive as of 2024 (approaches $3000/month)
IX. Resources
- Ensifentrine (DailyMed)
X. References
- (2024) Presc Lett 31(9): 51